Research and Development Expense of ALNYLAM PHARMACEUTICALS, INC. from 31 Mar 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
ALNYLAM PHARMACEUTICALS, INC. quarterly and annual Research and Development Expense in USD history and change rate from 31 Mar 2010 to 31 Dec 2025.
  • ALNYLAM PHARMACEUTICALS, INC. Research and Development Expense for the quarter ending 31 Dec 2025 was $372,218,000, a 24% increase year-over-year.
  • ALNYLAM PHARMACEUTICALS, INC. Research and Development Expense for the twelve months ending 31 Dec 2025 was $1,319,775,000, a 17% increase year-over-year.
  • ALNYLAM PHARMACEUTICALS, INC. annual Research and Development Expense for 2025 was $1,319,775,000, a 17% increase from 2024.
  • ALNYLAM PHARMACEUTICALS, INC. annual Research and Development Expense for 2024 was $1,126,232,000, a 12% increase from 2023.
  • ALNYLAM PHARMACEUTICALS, INC. annual Research and Development Expense for 2023 was $1,004,415,000, a 14% increase from 2022.
Source SEC data
View on sec.gov
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)

ALNYLAM PHARMACEUTICALS, INC. Quarterly Research and Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,319,775,000 $372,218,000 +$72,049,000 +24% 01 Oct 2025 31 Dec 2025 10-K 12 Feb 2026 2025 FY
Q3 2025 $1,247,726,000 $358,814,000 +$87,888,000 +32% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $1,159,838,000 $323,621,000 +$29,479,000 +10% 01 Apr 2025 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 $1,130,359,000 $265,122,000 +$4,127,000 +1.6% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $1,126,232,000 $300,169,000 +$28,028,000 +10% 01 Oct 2024 31 Dec 2024 10-K 12 Feb 2026 2025 FY
Q3 2024 $1,098,204,000 $270,926,000 +$17,747,000 +7% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025 2025 Q3
Q2 2024 $1,080,457,000 $294,142,000 +$45,616,000 +18% 01 Apr 2024 30 Jun 2024 10-Q 31 Jul 2025 2025 Q2
Q1 2024 $1,034,841,000 $260,995,000 +$30,426,000 +13% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $1,004,415,000 $272,141,000 +$10,102,000 +3.9% 01 Oct 2023 31 Dec 2023 10-K 12 Feb 2026 2025 FY
Q3 2023 $994,313,000 $253,179,000 +$7,808,000 +3.2% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 $986,505,000 $248,526,000 +$42,814,000 +21% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $943,691,000 $230,569,000 +$60,676,000 +36% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $883,015,000 $262,039,000 +$32,989,000 +14% 01 Oct 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
Q3 2022 $850,026,000 $245,371,000 +$50,799,000 +26% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $799,227,000 $205,712,000 +$23,077,000 +13% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $776,150,000 $169,893,000 -$16,006,000 -8.6% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $792,156,000 $229,050,000 +$60,581,000 +36% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $731,575,000 $194,572,000 +$32,789,000 +20% 01 Jul 2021 30 Sep 2021 10-Q 27 Oct 2022 2022 Q3
Q2 2021 $698,786,000 $182,635,000 +$27,639,000 +18% 01 Apr 2021 30 Jun 2021 10-Q 28 Jul 2022 2022 Q2
Q1 2021 $671,147,000 $185,899,000 +$16,328,000 +9.6% 01 Jan 2021 31 Mar 2021 10-Q 28 Apr 2022 2022 Q1
Q4 2020 $654,819,000 $168,469,000 -$32,832,000 -16% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $687,651,000 $161,783,000 +$987,000 +0.61% 01 Jul 2020 30 Sep 2020 10-Q 28 Oct 2021 2021 Q3
Q2 2020 $686,664,000 $154,996,000 -$8,894,000 -5.4% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $695,558,000 $169,571,000 +$40,444,000 +31% 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021 2021 Q1
Q4 2019 $655,114,000 $201,301,000 +$70,265,000 +54% 01 Oct 2019 31 Dec 2019 10-K 10 Feb 2022 2021 FY
Q3 2019 $584,849,000 $160,796,000 +$20,851,000 +15% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $563,998,000 $163,890,000 +$26,308,000 +19% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $537,690,000 $129,127,000 +$32,270,000 +33% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $505,420,000 $131,036,000 +$13,264,000 +11% 01 Oct 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
Q3 2018 $492,156,000 $139,945,000 +$44,693,000 +47% 01 Jul 2018 30 Sep 2018 10-Q 31 Oct 2019 2019 Q3
Q2 2018 $447,463,000 $137,582,000 +$46,955,000 +52% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $400,508,000 $96,857,000 +$9,873,000 +11% 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1
Q4 2017 $390,635,000 $117,772,000 +$12,761,000 +12% 01 Oct 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
Q3 2017 $377,874,000 $95,252,000 -$2,684,000 -2.7% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $380,558,000 $90,627,000 +$7,455,000 +9% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $373,103,000 $86,984,000 -$9,289,000 -9.6% 01 Jan 2017 31 Mar 2017 10-Q 04 May 2018 2018 Q1
Q4 2016 $382,392,000 $105,011,000 +$22,176,000 +27% 01 Oct 2016 31 Dec 2016 10-K 14 Feb 2019 2018 FY
Q3 2016 $360,216,000 $97,936,000 +$29,318,000 +43% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $330,898,000 $83,172,000 +$16,165,000 +24% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $314,733,000 $96,273,000 +$38,238,000 +66% 01 Jan 2016 31 Mar 2016 10-Q 05 May 2017 2017 Q1
Q4 2015 $276,495,000 $82,835,000 +$27,289,000 +49% 01 Oct 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
Q3 2015 $249,206,000 $68,618,000 +$22,345,000 +48% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $226,861,000 $67,007,000 +$22,335,000 +50% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2
Q1 2015 $204,526,000 $58,035,000 +$14,277,000 +33% 01 Jan 2015 31 Mar 2015 10-Q 04 May 2016 2016 Q1
Q4 2014 $190,249,000 $55,546,000 +$23,440,000 +73% 01 Oct 2014 31 Dec 2014 10-K 15 Feb 2017 2016 FY
Q3 2014 $166,809,000 $46,273,000 +$11,816,000 +34% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $154,993,000 $44,672,000 +$20,457,000 +84% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q1 2014 $134,536,000 $43,758,000 +$21,579,000 +97% 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015 2015 Q1
Q4 2013 $112,957,000 $32,106,000 +$10,428,000 +48% 01 Oct 2013 31 Dec 2013 10-K 12 Feb 2016 2015 FY
Q3 2013 $102,529,000 $34,457,000 +$12,363,000 +56% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q2 2013 $90,166,000 $24,215,000 +$2,492,000 +11% 01 Apr 2013 30 Jun 2013 10-Q 08 Aug 2014 2014 Q2
Q1 2013 $87,674,000 $22,179,000 +$1,105,000 +5.2% 01 Jan 2013 31 Mar 2013 10-Q 09 May 2014 2014 Q1
Q4 2012 $86,569,000 $21,678,000 -$1,691,000 -7.2% 01 Oct 2012 31 Dec 2012 10-K 13 Feb 2015 2014 FY
Q3 2012 $88,260,000 $22,094,000 -$2,180,000 -9% 01 Jul 2012 30 Sep 2012 10-Q 07 Nov 2013 2013 Q3
Q2 2012 $90,440,000 $21,723,000 -$3,580,000 -14% 01 Apr 2012 30 Jun 2012 10-Q 09 Aug 2013 2013 Q2
Q1 2012 $94,020,000 $21,074,000 -$5,275,000 -20% 01 Jan 2012 31 Mar 2012 10-Q 07 May 2013 2013 Q1
Q4 2011 $99,295,000 $23,369,000 -$2,711,000 -10% 01 Oct 2011 31 Dec 2011 10-K 20 Feb 2014 2013 FY
Q3 2011 $102,006,000 $24,274,000 -$3,194,000 -12% 01 Jul 2011 30 Sep 2011 10-Q 05 Nov 2012 2012 Q3
Q2 2011 $105,200,000 $25,303,000 -$2,833,000 -10% 01 Apr 2011 30 Jun 2011 10-Q 08 Aug 2012 2012 Q2
Q1 2011 $108,033,000 $26,349,000 +$1,649,000 +6.7% 01 Jan 2011 31 Mar 2011 10-Q 03 May 2012 2012 Q1
Q4 2010 $106,384,000 $26,080,000 01 Oct 2010 31 Dec 2010 10-K 19 Feb 2013 2012 FY
Q3 2010 $27,468,000 01 Jul 2010 30 Sep 2010 10-Q 03 Nov 2011 2011 Q3
Q2 2010 $28,136,000 01 Apr 2010 30 Jun 2010 10-Q 03 Aug 2011 2011 Q2
Q1 2010 $24,700,000 01 Jan 2010 31 Mar 2010 10-Q 05 May 2011 2011 Q1

ALNYLAM PHARMACEUTICALS, INC. Annual Research and Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $1,319,775,000 +$193,543,000 +17% 01 Jan 2025 31 Dec 2025 10-K 12 Feb 2026 2025 FY
2024 $1,126,232,000 +$121,817,000 +12% 01 Jan 2024 31 Dec 2024 10-K 12 Feb 2026 2025 FY
2023 $1,004,415,000 +$121,400,000 +14% 01 Jan 2023 31 Dec 2023 10-K 12 Feb 2026 2025 FY
2022 $883,015,000 +$90,859,000 +11% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $792,156,000 +$137,337,000 +21% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $654,819,000 -$295,000 -0.04% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $655,114,000 +$149,694,000 +30% 01 Jan 2019 31 Dec 2019 10-K 10 Feb 2022 2021 FY
2018 $505,420,000 +$114,785,000 +29% 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $390,635,000 +$8,243,000 +2.2% 01 Jan 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
2016 $382,392,000 +$105,897,000 +38% 01 Jan 2016 31 Dec 2016 10-K 14 Feb 2019 2018 FY
2015 $276,495,000 +$86,246,000 +45% 01 Jan 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
2014 $190,249,000 +$77,292,000 +68% 01 Jan 2014 31 Dec 2014 10-K 15 Feb 2017 2016 FY
2013 $112,957,000 +$26,388,000 +30% 01 Jan 2013 31 Dec 2013 10-K 12 Feb 2016 2015 FY
2012 $86,569,000 -$12,726,000 -13% 01 Jan 2012 31 Dec 2012 10-K 13 Feb 2015 2014 FY
2011 $99,295,000 -$7,089,000 -6.7% 01 Jan 2011 31 Dec 2011 10-K 20 Feb 2014 2013 FY
2010 $106,384,000 01 Jan 2010 31 Dec 2010 10-K 19 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.